Stockscreener 앱 받기
2.34
1.33%
0.08
시간 외 거래:
2.23
-0.11
-4.70%
Intensity Therapeutics Inc 주식(INTS)의 최신 뉴스
Equillium (NASDAQ:EQ) Stock Quotes, Forecast and News Summary - Benzinga
Intensity Infrastucture Partners Launches Open Season for New Natural Gas Transmission Pipeline to Serve the Bakken Region - Yahoo Finance
Clinical Trials News Live Feed - StockTitan
Drug Monitoring Committee Authorizes Continuation of Intensity T - GuruFocus.com
Intensity Therapeutics' sarcoma trial proceeds after review By Investing.com - Investing.com Canada
Intensity Therapeutics' sarcoma trial proceeds after review - Investing.com India
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review - Nasdaq
High Intensity Focused Ultrasound Market Forecast and Company Analysis 2025-2033 Featuring Koninklijke Philips, Johnson & Johnson, Hitachi, General Electrics, Medtronic, Stryker, EDAP TMS, Theraclion - Yahoo Finance
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Soft Tissue Sarcoma Market Poised for Significant Growth from - openPR
Soft Tissue Sarcoma Pipeline Review 2024: Clinical Trials - openPR
Alliance Global Partners Initiates Coverage of Intensity Therapeutics (INTS) with Buy Recommendation - MSN
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 - PR Newswire
Avoiding Isolation By Volunteering Offers Mental Health Benefits to Seniors - 69News WFMZ-TV
Retrospective Analysis of Dosimetric Comparison Between Intensity-Modulated Radiation Therapy and Volumetric-Modulated Arc Therapy in Patients With Esophageal Cancer - Cureus
Intensity Therapeutics stock hits 52-week low at $1.73 By Investing.com - Investing.com Australia
Intensity Therapeutics stock hits 52-week low at $1.73 - Investing.com
Internal Radiation Therapy - Market.us
Exicure joins hands with GPCR Therapeutics for growth in biotech (NASDAQ:XCUR) - Seeking Alpha
Myelodysplastic Syndrome (MDS) Drugs Market Trends and Sales Forecast to 2030: Total Revenues to Reach US$4.1 Billion Worldwide, with Immunomodulatory Drugs Dominating Shares - GlobeNewswire
Intensity Therapeutics Stock Hits 52-Week Low at $1.76 By Investing.com - Investing.com Australia
Intensity Therapeutics Stock Hits 52-Week Low at $1.76 - Investing.com
Top pharma biotech companies R&D intensity globally 2023 - Statista
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List - Yahoo Finance
Intensity Therapeutics reports positive results of INT230-6 in breast cancer - Yahoo Finance
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients - Yahoo Finance
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - Insider Monkey
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - Yahoo Finance
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Brea - Yahoo Finance
2.95%
0.31%
자본화:
|
볼륨(24시간):